10-Q: Mountain Crest Acquisition Corp. V Reports First Quarter 2024 Results and Provides Business Combination Update

Mountain Crest Acquisition Corp. V released its first quarter 2024 financial results, showing a net loss of $25,537 and provided an update on its business combination plans.

Summary

• Mountain Crest Acquisition Corp. V reported a net loss of $25,537 for the three months ended March 31, 2024, compared to a net loss of $43,336 for the same period in 2023.
• The company's operating costs were $83,769, offset by interest income of $73,585 from investments held in the Trust Account.
• The company has extended its deadline to complete a business combination to November 16, 2024, by making additional deposits into its trust account.
• As of March 31, 2024, the company held $5,738,912 in its Trust Account, primarily invested in money market funds.
• The company has entered into a business combination agreement with CUBEBIO Co., Ltd., with a potential closing date no later than May 15, 2025.
• The company has been working to regain compliance with Nasdaq listing requirements after receiving notices of non-compliance.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has secured a business combination agreement and regained compliance with a listing rule, it also faces significant challenges including a net loss, ineffective controls, material weaknesses, listing compliance issues, and going concern uncertainty. The sentiment is therefore cautiously negative.

Positives

• The company has secured a business combination agreement with CUBEBIO Co., Ltd.
• The company has regained compliance with Nasdaq's MVLS rule.
• The company has extended its business combination deadline to November 16, 2024, providing more time to complete a transaction.
• The company's net loss decreased compared to the same period last year.

Negatives

• The company reported a net loss of $25,537 for the first quarter of 2024.
• The company's disclosure controls and procedures were deemed not effective.
• The company has identified material weaknesses in internal controls.
• The company has received notices from Nasdaq regarding non-compliance with listing rules.
• The company has a limited cash balance outside of the trust account for working capital purposes.

Risks

• The company's ability to continue as a going concern is in doubt if a business combination is not completed by November 16, 2024.
• The company's disclosure controls and procedures were not effective, indicating potential issues with financial reporting.
• The company has identified material weaknesses in internal controls, which could lead to further financial reporting issues.
• The company has received notices from Nasdaq regarding non-compliance with listing rules, which could lead to delisting.
• The company may need to raise additional capital to complete the business combination.
• The company is subject to risks associated with early-stage and emerging growth companies.
• The company is exposed to potential impacts from the COVID-19 pandemic and geopolitical conflicts.

Future Outlook

The company intends to complete its business combination with CUBEBIO Co., Ltd. by the deadline of May 15, 2025, or earlier, and is working to regain compliance with Nasdaq listing requirements.

Management Comments

• Management has determined that the liquidity condition and mandatory liquidation, should a Business Combination not occur, and potential subsequent dissolution, raises substantial doubt about the Companys ability to continue as a going concern.
• Management is working diligently to complete and file the Form 10-K and the Form 10-Q as soon as practicable.

Industry Context

The company is a special purpose acquisition company (SPAC) seeking to merge with a private company. The current market conditions for SPACs are challenging, with increased scrutiny and regulatory oversight. The company's efforts to extend its timeline and secure a business combination are consistent with the broader trend of SPACs seeking to complete transactions before their deadlines.

Comparison to Industry Standards

• The company's financial performance is typical for a SPAC in its pre-merger phase, with minimal operating activity and reliance on interest income from its trust account.
• The company's efforts to extend its timeline and secure a business combination are consistent with the broader trend of SPACs seeking to complete transactions before their deadlines.
• The company's challenges with Nasdaq listing compliance are not uncommon for SPACs, particularly those that have experienced redemptions.
• The company's reliance on sponsor loans for working capital is a common practice among SPACs.

Related Party Transactions

• The company has entered into multiple promissory notes with its sponsor for working capital.
• The company has an administrative support agreement with its sponsor.
• The company converted a promissory note to the sponsor into 75,000 shares of common stock.
• The company converted vendor liabilities into 450,000 shares of common stock.

Stakeholder Impact

• Shareholders face the risk of liquidation if a business combination is not completed by November 16, 2024.
• Shareholders may experience dilution if additional shares are issued to complete the business combination.
• Employees of the company are impacted by the uncertainty surrounding the company's future.
• Creditors of the company may be impacted by the company's financial condition and ability to repay debts.
• The target company, CUBEBIO, is impacted by the uncertainty surrounding the closing of the business combination.

Next Steps

• The company needs to complete the business combination with CUBEBIO Co., Ltd.
• The company needs to regain compliance with Nasdaq listing requirements.
• The company needs to file its delayed Form 10-K and Form 10-Q reports.
• The company needs to address the material weaknesses in internal controls.
• The company needs to secure additional financing if required.

Key Dates

Keywords

Business Combination, SPAC, CUBEBIO, Nasdaq, Financial Results, Trust Account, Promissory Notes, Redemption, Listing Compliance, Internal Controls